Eswar R Reddem
Overview
Explore the profile of Eswar R Reddem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
536
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong S, Resnick S, Iketani S, Cha J, Albert B, Fazekas C, et al.
Mol Syst Biol
. 2025 Jan;
21(2):158-172.
PMID: 39762652
With current treatments addressing only a fraction of pathogens and new viral threats constantly evolving, there is a critical need to expand our existing therapeutic arsenal. To speed the rate...
2.
Liu L, Casner R, Guo Y, Wang Q, Iketani S, Chan J, et al.
Immunity
. 2023 Sep;
56(10):2442-2455.e8.
PMID: 37776849
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities against the virus, we screened serum samples from convalescing COVID-19...
3.
Liu L, Casner R, Guo Y, Wang Q, Iketani S, Chan J, et al.
bioRxiv
. 2023 Apr;
PMID: 37090592
SARS-CoV-2 continues to evolve and evade most existing neutralizing antibodies, including all clinically authorized antibodies. We have isolated and characterized two human monoclonal antibodies, 12-16 and 12-19, which exhibited neutralizing...
4.
Luo M, Zhou B, Reddem E, Tang B, Chen B, Zhou R, et al.
Emerg Microbes Infect
. 2022 Nov;
12(1):2146538.
PMID: 36354024
Increasing spread by SARS-CoV-2 Omicron variants challenges existing vaccines and broadly reactive neutralizing antibodies (bNAbs) against COVID-19. Here we determine the diversity, potency, breadth and structural insights of bNAbs derived...
5.
Gierse R, Oerlemans R, Reddem E, Gawriljuk V, Alhayek A, Baitinger D, et al.
Sci Rep
. 2022 May;
12(1):7221.
PMID: 35508530
The development of drug resistance by Mycobacterium tuberculosis and other pathogenic bacteria emphasizes the need for new antibiotics. Unlike animals, most bacteria synthesize isoprenoid precursors through the MEP pathway. 1-Deoxy-D-xylulose...
6.
Liu L, Iketani S, Guo Y, Reddem E, Casner R, Nair M, et al.
Sci Transl Med
. 2022 Apr;
14(646):eabn6859.
PMID: 35438546
The devastation caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made clear the importance of pandemic preparedness. To address future zoonotic outbreaks due to related viruses in the...
7.
Madan B, Reddem E, Wang P, Casner R, Nair M, Huang Y, et al.
AIChE J
. 2021 Dec;
67(12):e17440.
PMID: 34898670
Antiviral monoclonal antibody (mAb) discovery enables the development of antibody-based antiviral therapeutics. Traditional antiviral mAb discovery relies on affinity between antibody and a viral antigen to discover potent neutralizing antibodies,...
8.
Cerutti G, Guo Y, Wang P, Nair M, Wang M, Huang Y, et al.
Cell Rep
. 2021 Oct;
37(5):109928.
PMID: 34706271
Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies have been studied structurally, and all target a...
9.
Banach B, Cerutti G, Fahad A, Shen C, de Souza M, Katsamba P, et al.
Cell Rep
. 2021 Sep;
37(1):109771.
PMID: 34587480
Understanding mechanisms of protective antibody recognition can inform vaccine and therapeutic strategies against SARS-CoV-2. We report a monoclonal antibody, 910-30, targeting the SARS-CoV-2 receptor-binding site for ACE2 as a member...
10.
Cerutti G, Guo Y, Wang P, Nair M, Huang Y, Yu J, et al.
bioRxiv
. 2021 Jul;
PMID: 34230927
Highlights: Cryo-EM structure of neutralizing antibody 5-7 in complex with SARS CoV-2 spike5-7 recognizes NTD outside of the previously identified antigenic supersite5-7 binds to a site known to accommodate numerous...